loading...| Preferred Name |
Duloxetine Hydrochloride |
|
| Synonyms |
|
|
| Definitions |
The hydrochloride salt of duloxetine, a fluoxetine derivative belonging to the class of selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors (SSNRIs) and exhibiting antidepressant activity. Duloxetine selectively prevents the reuptake of 5-HT and NE via transporter complexes on the pre-synaptic membrane, thereby increasing the level of these neurotransmitters within the synaptic cleft. As a result, this agent potentiates serotonergic and noradrenergic activities in the central nervous system, and alleviates depression and neuropathy sensations, such as pain and tingling. Furthermore, duloxetine does not show significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and gamma-aminobutyric acid (GABA) receptors. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C65496 |
|
| ALT_DEFINITION |
A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Duloxetine hydrochloride increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor. |
|
| CAS_Registry |
136434-34-9 |
|
| CHEBI_ID |
CHEBI:31526 |
|
| Chemical_Formula |
C18H19NOS.HCl |
|
| code |
C65496 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The hydrochloride salt of duloxetine, a fluoxetine derivative belonging to the class of selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors (SSNRIs) and exhibiting antidepressant activity. Duloxetine selectively prevents the reuptake of 5-HT and NE via transporter complexes on the pre-synaptic membrane, thereby increasing the level of these neurotransmitters within the synaptic cleft. As a result, this agent potentiates serotonergic and noradrenergic activities in the central nervous system, and alleviates depression and neuropathy sensations, such as pain and tingling. Furthermore, duloxetine does not show significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and gamma-aminobutyric acid (GABA) receptors. |
|
| Display_Name |
Duloxetine Hydrochloride |
|
| FDA_UNII_Code |
9044SC542W |
|
| Has_Free_Acid_Or_Base_Form | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C176424 |
|
| label |
Duloxetine Hydrochloride |
|
| Legacy Concept Name |
Duloxetine_Hydrochloride |
|
| NCI_Drug_Dictionary_ID |
553629 |
|
| PDQ_Closed_Trial_Search_ID |
553629 |
|
| PDQ_Open_Trial_Search_ID |
553629 |
|
| Preferred_Name |
Duloxetine Hydrochloride |
|
| prefixIRI |
NCIT:C65496 |
|
| prefLabel |
Duloxetine Hydrochloride |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C1505020 |
|
| subClassOf |